Clinical trials: sponsored by Jonsson Comprehensive Cancer Center
Breast Cancer
Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00066547
- Testing
- monoclonal antibody HuHMFG1
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from a person's white blood cells and a donor's tumor cells may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00107159
- Testing
- autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Graft Versus Host Disease, Leukemia
Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
RATIONALE: Giving chemotherapy and total-body irradiation before a donor bone marrow transplant or peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00093587
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Cancer
INS316 Compared With Saline for Sputum Collection in Diagnosing Lung Cancer
RATIONALE: INS316 may produce a better sputum sample for laboratory analysis and may provide a less invasive method of diagnosing lung cancer.
- Trial name
- NCT00033527
- Testing
- INS316, sputum cytology
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Low-Fat, High-Fiber Diet Compared to a Standard Diet in Treating Patients With Prostate Cancer
RATIONALE: A low-fat, high-fiber diet may slow the growth of prostate cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of a low-fat, high-fiber diet with that of a standard diet in treating patients who…
- Trial name
- NCT00020995
- Testing
- therapeutic dietary intervention
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of carbendazim in treating patients who have advanced…
- Trial name
- NCT00023816
- Testing
- carbendazim
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Cancer
Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Celecoxib may stop the growth of cancer by stopping blood flow to the tumor. Erlotinib and celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Trial name
- NCT00072072
- Testing
- celecoxib, erlotinib hydrochloride
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004115
- Testing
- yttrium Y 90 monoclonal antibody HMFG1
- Where
- United Kingdom
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Cancer, Lymphoma
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: AMG 706 may stop the growth of cancer cells by blocking blood flow to the cancer or by blocking some of the enzymes needed for cell growth.
- Conditions
- Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00324597
- Testing
- gemcitabine hydrochloride, motesanib diphosphate, pharmacological study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Folic acid may protect normal cells from the side effects of chemotherapy and may increase the effectiveness…
- Trial name
- NCT00024310
- Testing
- folic acid, lometrexol, paclitaxel
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Vaccines made from a person's peripheral stem cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have…
- Trial name
- NCT00005992
- Testing
- PSA prostate cancer vaccine, therapeutic autologous dendritic cells
- Where
- 2 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Colorectal Cancer
Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of tocladesine in treating patients who have recurrent or…
- Trial name
- NCT00021268
- Testing
- tocladesine
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma
RATIONALE: Drugs used in chemotherapy, such as gimatecan, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087061
- Testing
- gimatecan
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Anemia, Lung Cancer
Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Ro 50-3821 may stimulate red blood cell production and treat anemia in patients who are receiving antineoplastic therapy for non-small cell lung cancer.
- Trial name
- NCT00072059
- Testing
- methoxy polyethylene glycol epoetin beta
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Anemia, Breast Cancer
Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Epoetin alfa may stimulate red blood cell production to treat patients who have anemia following chemotherapy. PURPOSE: Phase IV trial to study the effectiveness of epoetin alfa in treating chemotherapy-related anemia…
- Conditions
- Anemia, Breast Cancer, Fatigue
- Trial name
- NCT00022386
- Testing
- epoetin alfa, quality-of-life assessment
- Sponsor
- Jonsson Comprehensive Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of exatecan mesylate in treating patients who have advanced…
- Trial name
- NCT00045318
- Testing
- exatecan mesylate
- Where
- 5 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer
BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer
RATIONALE: BAY 56-3722 may stop the growth of cancer cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of BAY 56-3722 in treating patients who have recurrent…
- Trial name
- NCT00040989
- Testing
- BAY 56-3722, enzyme inhibitor therapy
- Where
- 26 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Leukemia
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
RATIONALE: Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00100997
- Testing
- tanespimycin
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer
Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer
RATIONALE: Monoclonal antibodies such as HuHMFG1 can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00096057
- Testing
- monoclonal antibody HuHMFG1
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Vaccine Therapy in Treating Patients With Advanced Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced cancer.
- Trial name
- NCT00004881
- Testing
- MVA-MUC1-IL2 vaccine
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center